Top

Published in:

01-04-2021 | Multiple Sclerosis | Original Article

Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants

Authors: B. B. Newbould, C. M. Pearson, M. W. Whitehouse

Published in: Inflammopharmacology | Issue 2/2021

Abstract

A strategy is described for evaluating drugs against different phases in the development of an auto allergic disease, experimental allergic encephalomyelitis. It is based on a cell transfer technique whereby the disease is passively transferred with lymphoid cells from actively immunized donor rats to normal syngeneic rats = passive recipients. Drugs may be applied in vivo to either the cell donors or the cell recipients or to cells in vitro whilst in transit; their efficiency being determined by the severity of the passive disease (weight loss, paralysis) in the recipients.

Examples are given illustrating the application of these techniques to:

(a)

evaluating the lymphocyte-deactivating activity of various nitrogen mustards in vitro;

(b)

recognizing drugs, e.g. gold derivatives, clofazimine, etc. that are not conventional immunosuppressant (or cytostatic) agents which, when given to the recipient animals, may prevent the expression of the adopted disease;

(c)

comparing some known immunosuppressants for potency, duration of action, etc.;

(d)

demonstrating the versatility of cycloleucine, ICI-47,776, etc.

Some merits of the strategy are discussed vis a vis using the local graft-versus-host reaction in rats to search for new drugs.

Available only for authorised users

EN 3638 is 6-hydroxyphthalaldehydic acid, 0-(p.chlorobenzyl) oxime. Clofazimine (B-7663, Lamprene^®) was somewhat more effective when given for seven days prior to cell transfer, rather than after cell transfer; paralleling the effect of this drug in suppressing adjuvant arthritis (Currey ans Fowler 1972).

Albert A (1973) Selective Toxicity, 5th edn. Chapman and Hall, LondonCrossRef

Baxter AG (2007) The origin and application of experimental autoimmuno encephalomyelitis. Nature Rev Immunol 7:904–912CrossRef

Beck FJ, Levy L, Whitehouse MW (1973) The local graft versus host reaction in the rat as a tool for drug mechanism studies. Brit J Pharmacol 49:293–302CrossRef

Broadley SA, Barnett MH, Boggild M et al (2015) A new era in the treatment of multiple sclerosis. Med J Austr 203:139–141CrossRef

Cock IE, Cheesman MJ (2018) The potential of plants of the genus Syzygium (Myrtaceae) for the prevention and treatment of arthritic and autoimmune diseases IN Bioactive foods as dietary interventions for arthritis, osteoarthritis, and related autoimmune diseases, 2nd edn. (Eds VR Preedy, RR Watson), Elsevier, Cambridge

Constantinescu CS, Farooqi N, O’Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis(MS). Br J Pharmacol 164:1079–1106CrossRef

Currey HLF, Fowler PD (1972) A study of clofazimine in the rat. Brit J Pharmacol 65:676–681CrossRef

Davies GE (1968) Immunosuppressive activity of 3-acetyl-5(4-fluoro benzylidene)-hydroxy-2-oxo-2:5-dihyrothiophen (ICI-47,776). Immunol 14:393–399

Franklin TJ, Newbould BB, O’Mant DM, Scott AI, Stacey GJ, Davies GE (1966) A new type of cytotoxic immunosuppressant agent: 3-acetyl-5 (4-fluorobenzylidene)-4-hydroxy-2-oxo-2:5 dihydrothiophen. Nature 210:638–639CrossRef

Denic A, Johnson AJ, Bieber AJ, Warrington AE et al (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18:21–29CrossRef

Ebringer A (2015) Multiple Sclerosis ‘Mad Cow Disease’ and Acinetobacter. Springer, LondonCrossRef

Friedman M, Krull LH, Cavins JF (1970) The chromatographic determination of cysteine and half-cysteine residues in proteins as S- -(4-pyridytlethyl)-L-cysteine. J Biol Chem 245:3868–3871CrossRef

Gerber RC, Orr KJ, Whitehouse MW (1972) Effect of gold preparations on the development and passive transfer of experimental allergic encephalomyelitis in rats. Proc Soc Exp Biol Med 140:1379–1384CrossRef

Ghosh PB, Whitehouse MW (1969) Potential antileukemic and immunosuppressive drugs II. Further studies with Benzo-2,1,3-oxadiazoles and their N-oxides. J Med Chem 12:505–507CrossRef

Lassman H (2018) Experimental models of multiple sclerosis. Sci Rep 8:13628. https://doi.org/10.1038/s4159-018-31957-7CrossRef

Levine S, Wenk EJ (1965) A hyperacute form of allergic encephalomyelitis. Am J Path 47:61–88PubMed

Mandeville A, Cock IE (2018) Terminalia chebula food extracts inhibit bacterial triggers for some autoimmune diseases. Ind J Microbiol 58:496–506CrossRef

Mehrishi JN, Grassetti DR (1969) Sulphydryl groups on the surface of intact Ehrlich ascites tumour cells, human blood platelets and lymphocytes. Nature 224:563–564CrossRef

Newbould BB (1965) Production of allergic encephalomyelitis in rats by injection of spinal cord adjuvant into the inguinal lymph nodes. Immunology 56:613–614

Newbould BB, Pearson CM, Van de Sande B (1969) Effect of immunosuppression on allergic encephalomyelitis in rats and of immunosuppressive drugs on the cell-mediated transfer of the disease. Arthr Rheum 12:683

Paterson PY (1960) Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 111:119–135CrossRef

Paterson PY (1966) Experimental allergic encephalomyelitis and auto-immune disease. Adv Immunol 5:131–218CrossRef

Paterson PY (1968) Experimental auto-immune allergic encephalomyelitism. In: Miescher PA, Muller-Eberhar HJ (eds) Textbook of Immunopathology. Grune and Stratton, New York, pp 132–149

Paterson PY, Drobish DG (1969) Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science 106:191–192CrossRef

Paterson PY, Hanson MA (1969) Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J Immunol 103:1311–1316PubMed

Rosenthale ME (1974) Evaluation for immunosuppressant and anti-allergic activity. In: Scherrer RA, Whitehouse MW (eds) Anti-Inflammatory Agents. Academic Press, New York, pp 123–192CrossRef

Rosenthale ME, Datko LJ, Kasserich J, Schneider F (1969) Chemotherapy of experimental allergic encephalomyelitis (EAE). Arch int Pharmacodyn 179:251–275PubMed

Rosenthale ME, Atko LJ, Kasserich J, Rosanoff EL (1972) Immunopharmacologic effects of cycloleucine. J Pharmacol exptl Therap 180:501–513

Samter M (ed) (1971) Immunological diseases. Little Brown, Boston

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM et al (2016) Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA 113:4777–4782CrossRef

Sirdaata J, Mathews B, White A, Cock IE (2015) GC-MS and LC-MS analysis of Kakadu plum fruit extracts displaying inhibitory activity against microbial triggers of multiple sclerosis. Pharmacog Commn 5:100–115CrossRef

Smith SB, Waksman BH (1969) Passive transfer and labelling studies on the cell infiltrates in experimental allergic encephalomyelitis. J Pathol 23:237–244CrossRef

Udenfriend S, Clark CT, Axelrod J, Brodie BB (1954) Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 208:731–739CrossRef

Whitehouse MW (1971) Biochemical studies of flumefenine. HC1 (R-760 Flazalone), a new anti-inflammatory drug. Proc W Parmacol Soc 6:55–57

Whitehouse MW, Doskotch RW (1969) Selective inhibition of thymidine incorporation into lymphocytes by cucurbitacins B and D. Biochem Pharmacol 18:1790–1793CrossRef

Whitehouse DJ, Whitehouse MW, Pearson CM (1969) Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature 224:1322CrossRef

Whitehouse MW, Droge MM, Struck RF (1972) Potential immunosuppressant activity of cyclophosphamide metabolites. Abstr Int Congr Pharmacol 5:251

Whitehouse MW, Levy L, Beck FJ (1973) Effect of cyclophosphamide on a local graft-versus-host reaction in the rat: influence of sex, disease and different dosage regimens. Agents Act 3:53–60CrossRef

Whitehouse MW, Orr KJ, Beck FJ, Pearson CM (1974) Freund’s adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunol 27:311–330

Yu DTY, Whitehouse MW (1973) Effect of some nitrogen mustards and thoracic duct drainage on lymphocyte distribution in rats. Int Arch Allergy Appl Immunol 46:172–182CrossRef

Title: Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants
Authors: B. B. Newbould
C. M. Pearson
M. W. Whitehouse
Publication date: 01-04-2021
Publisher: Springer International Publishing
Keyword: Multiple Sclerosis
Published in: Inflammopharmacology / Issue 2/2021
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-019-00565-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Quercetin inhibits caerulein-induced acute pancreatitis through regulating miR-216b by targeting MAP2K6 and NEAT1

Anti-inflammatory effects of Chrysophyllum cainito fruit extract in lipopolysaccharide-stimulated mouse peritoneal macrophages

HPLC–ESI–QTOF–MS/MS profiling and therapeutic effects of Schinus terebinthifolius and Schinus molle fruits: investigation of their antioxidant, antidiabetic, anti-inflammatory and antinociceptive properties

Neuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation

Correction to: COVID‑19 and therapy with essential oils having antiviral, anti‑inflammatory, and immunomodulatory properties

Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington’s disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway